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Perivascular epithelioid cell tumor (PEComa) is a rare and re-
cently described neoplasm composed mainly of epithelioid cells 
with a characteristic perivascular pattern of arrangement.1 The 
diagnosis can be confirmed by immunohistochemical (IHC) 
staining as tumor cells express melanocytic and myogenic 
markers.2 These tumors can occur in a wide variety of organs 
including the kidney, liver, lung, uterus, and pancreas.3 We re-
port the case of a PEComa arising from the sacral bone, which 
is an exceedingly rare site for a PEComa. Although there have 
been several reports of PEComas originating from bone, to our 
knowledge this is the first case report of a PEComa arising from 
the sacral bone.4
CASE REPORT
A 45-year-old man without relevant medical history present-
ed with left buttock and leg pain 1.5 months in duration. Sacral 
magnetic resonance imaging revealed a 5.5×4.7-cm lobulated 
osteolytic expansile mass on the left side of the sacrum (Fig. 
1A). The tumor was invading the lumbo-sacral spinal canal 
medially via neural foramens S1-3 and laterally via the left sac-
roiliac joint. Positron emission tomography showed increased 
fluorodeoxyglucose uptake, suggesting malignancy. Due to the 
radiologic characteristics, a germ cell tumor or nerve sheath tu-
mor was considered. An excisional surgery was performed, and 
intraoperatively the tumor was found to be solid and multilob-
ulated, and was covered with a thin vascularized capsule. It was 
easily separated from the sacral nerve roots and sacral bone, thus 
allowing for near total removal. The tumor bed was then treat-
ed with postoperative radiation therapy (64.8 Gy) without 
complication.
The tumor was relatively poorly demarcated from normal tis-
sue and showed rich networks of arborizing sinusoidal capillar-
ies. It was composed exclusively of polygonal and epithelioid 
cells with abundant clear to eosinophilic cytoplasm, most of 
which was arranged in sheets or a vague nesting pattern (Fig. 
1B). Occasional perivascular arrangements were also noted (Fig. 
1C). Infiltration into adjacent bone tissue was found (Fig. 1D), 
but no necrosis or mitosis was observed. The initial differential 
diagnosis included ependymoma, hemangioblastoma, paragan-
glioma, and epithelioid neurogenic tumor. Many IHC stains 
were performed, but none of the tumor cells showed immuno-
reactivity to antibodies except smooth muscle actin (SMA) (Fig. 
2A). Several additional IHC stains were done and human mela-
noma black 45 (HMB45) and transcription factor E3 (TFE3) 
were found to be expressed by the tumor cells (Fig. 2B, C), but 
the tumor was negative for Melan A (Fig. 2D). With these IHC 
results, a confirmative diagnosis of PEComa was established.
DISCUSSION
PEComa is an uncommon tumor that can occur in various 
organs, with the uterus being a representative primary site of 
PEComa. Angiomyolipoma of the kidney and liver, and clear 
cell tumor of the lung are also regarded to originate from peri-
vascular epithelioid cells. When this tumor arises in other or-
gans it can be difficult to diagnose. In this case, PEComa was 
not included in the initial differential diagnosis. Moreover, 
perivascular arrangements, the most unique characteristic of a 
PEComa, were not prominent in this case because they were 
masked by the diffuse and sheet-like growth patterns of tumor 
cells. Initial IHC stains were not informative, so additional 
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stains were performed which allowed for the eventual diagnosis 
of PEComa.
Diagnosis of PEComa is quite challenging and requires a 
combination of attention to morphologic detail and the appro-
priate use of melanocytic and myogenic markers, such as 
HMB45, Melan A, and SMA. TFE3, a melanocytic marker, can 
also be expressed in PEComa. However, malignant melanoma 
(MM) and clear cell sarcoma (CCS) can exhibit a similar IHC 
profile, which remains a diagnostic dilemma. Distinguishing 
between these tumors is important because the majority of 
PEComas follow a benign clinical course in contrast to the poor 
prognosis of MM and CCS, although rare malignant PEComas 
do occur.2 MM can have similar morphological patterns to 
PEComa and shares IHC profiles including HMB45, Melan A, 
and TFE3. Furthermore, SMA, a marker generally negative in 
melanoma, has been reported to be expressed in a desmoplastic 
variant of MM.5 S100 has been proposed as a useful marker be-
cause it is expressed in MM, but not in PEComa, even though a 
small subset of PEComas was found to express it.2 Multiple 
myeloma 1 (MUM1), a B-cell proliferation marker, also can be 
used because of its expression in the majority of MMs in con-
trast to the significantly diminished or absent expression seen 
in PEComa.6,7 Therefore, the addition of S100 protein and 
MUM1 to IHC panels could be helpful in the differential diag-
nosis between these lesions. In our case, the tumor cells were 
positive for SMA and negative for S100 protein and MUM1, 
which supported a diagnosis of PEComa rather than of MM. 
CCS can also mimic PEComa morphologically and express me-
lanocytic markers. However, CCS can be distinguished from 
PEComa because SMA is consistently negative in CCS.
This case is noteworthy in that the tumor cells of a PEComa 
exhibited TFE3 expression. TFE3 is a member of microphthal-
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Fig. 1. Representative radiological and histological images of the tumor. (A) Axial view of a three-dimensional sacral magnetic resonance im-
age showing a 5.5×4.7-cm lobulated and expansile mass. (B) The tumor cells exhibit round to polygonal nuclei with eosinophilic cytoplasm 
and a sheet-like growth pattern. (C) Tumor cells with clear cytoplasm show perivascular arrangements, suggesting a diagnosis of perivascu-
lar epithelioid cell tumor. (D) Adjacent bone tissue is infiltrated by tumor cells.
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Fig. 2. Results of immunohistochemistry. Smooth muscle actin (A), human melanoma black 45 (B), and transcription factor E3 (C) are ex-
pressed in tumor cells. (D) Melan A is negative.
mia transcription factor family and has been associated with 
several neoplastic conditions including alveolar soft part sarco-
ma (ASPS), Xp11 translocation renal cell carcinoma and PECo-
ma.8,9 The likelihood of ASPS was considered to be low in this 
case because the cell nuclei were less atypical than those usually 
seen in ASPS, no crystalloid material was detected on periodic 
acid-Schiff stain and HMB45 was clearly positive.2 Recently, 
Argani et al.10 presented distinctive features of TFE3-positive 
PEComa, which included relatively young patient age, pre-
dominant nesting architecture with epithelioid cytology, lack of 
nuclear anaplasia or pleomorphism, weak positivity to IHC 
stains for smooth muscle markers and absence of a tuberous 
sclerosis complex. Our case shares several clinicopathologic as-
pects with previously reported cases.
Although most PEComas have a benign clinical course, sev-
eral cases with local invasion, recurrence and even distant me-
tastasis have been reported.2 At this point, the biologic behavior 
of PEComa is unclear. Recently, Folpe et al.2 proposed criteria 
for estimating the malignant potential of PEComa. According 
to that report, tumors with large size (more than 5 cm), infiltra-
tive margins, nuclear pleomorphism, mitosis, and necrosis may 
be more aggressive. In this case, the tumor consisted of monot-
onous tumor cells without nuclear atypia, mitosis or necrosis. 
However, it was regarded as at least a borderline or low-grade 
malignancy because it was larger than 5 cm and had an ill-de-
fined tumor border.
The significance of this case is the rare site of occurrence. Al-
though this disease can occur in a wide range of anatomic sites, 
bone as a primary site of a PEComa is very unusual. There have 
been several reports concerning PEComas arising from skeletal 
tissue, including the skull, rib and fibula. The sacrum, however, 
has never been reported as a primary site of a PEComa, and ours 
is the first reported case of a PEComa arising in this location. 
Diagnosing PEComas at unusual sites can be challenging for 
pathologists, particularly if this disease is not suspected in the 
initial differential diagnosis.
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